Latest Intellectual Property News

TG Metals has lodged a provisional patent application for a new technology that significantly improves lithium recovery and concentrate quality at its Burmeister deposit in Western Australia.

Acusensus Limited has settled its patent litigation with Redflex Traffic Systems, issuing over six million shares and paying US$6 million in cash to resolve the dispute. The agreement clears the way for Acusensus to continue its road safety technology operations unimpeded.

Careteq Limited has agreed to sell its Embedded Health Solutions business for $5 million, aiming to strengthen its balance sheet and focus on expanding its home medication review platform amid ongoing tax disputes.

WRKR Ltd has completed its strategic acquisition of PaidRight Holdings, issuing over 90 million shares to expand its compliance platform into payroll compliance. This move marks a significant step beyond superannuation, aiming to create a comprehensive compliance solution.

Anax Metals is set to release an updated feasibility study for its Whim Creek project, reflecting soaring commodity prices and progressing funding talks to push the project into development.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Adisyn Ltd has appointed Arye Kohavi, CEO of 2D Generation, as its new Managing Director to spearhead its semiconductor technology strategy following a strategic review and recent acquisition.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

FortifAI Limited has completed its acquisition of FastAI Pty Ltd, gaining control of the innovative Nol8 technology and appointing seasoned executive Yosef Keret as director and Celerriem CEO.

Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.